nalmefene: Clinical Trials

14 trials of nalmefene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 terminated. 14 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Completed 13, Terminated 1
Phase 21Completed 1

Follow nalmefene: new trials by email Literature Review of nalmefene trials Research Report on nalmefene

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection - Opioid Overdose
Phase 1CompletedKnoa Pharma LLC132026-02-062026-06-05
An Evaluation of The Absolute Bioavailability of TH104
Nalmefene - Healthy
Phase 1CompletedTharimmune Inc202024-01-262025-04-08
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
Nalmefene HCl injection, Naloxone HCl intranasal - Opioid Overdose
Phase 1CompletedPurdue Pharma LP242022-10-032025-07-03
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
Narcan 40 MG/ML Nasal Spray, Naloxone Hydrochloride, Nalmefene HCl injection - Opioid Induced Respiratory Depression, Chronic Opioid Use
Phase 1TerminatedLeiden University Medical Center582022-06-242026-07-29
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
Nalmefene Hydrochloride - Opioid Overdose
Phase 1CompletedOpiant Pharmaceuticals Inc242021-09-012024-08-05
Pharmacodynamic Evaluation of Intranasal Nalmefene
Nalmefene hydrochloride, Naloxone hydrochloride - Pharmacodynamic
Phase 1CompletedOpiant Pharmaceuticals Inc842021-03-302025-07-14
Pharmacokinetic Evaluation of Intranasal Nalmefene
Nalmefene Hydrochloride, Nalmefene - Pharmacokinetics
Phase 1CompletedOpiant Pharmaceuticals Inc682021-02-082024-08-13
St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene
Low dose naltrexone, Nalmefene - HIV Infection, Alcohol Use
Phase 1 / Phase 2CompletedBoston Medical Center112018-07-032020-08-24
Patient Driven Recovery With Nalmefene and Coaching
Nalmefene - Opioid-use Disorder, Harmful; Use, Alcohol
Phase 1CompletedYale University102017-09-012021-01-22
Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers
Nalmefene - Opioid-Related Disorders
Phase 1CompletedNational Institute on Drug Abuse (NIDA)142017-06-012018-03-26
Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation
Nalmefene, Placebo - AUD
Phase 1CompletedNational Institute on Alcohol Abuse and Alcoholism (NIAAA)132016-06-082026-10-29
A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects
nalmefene hydrochloride 10 mg - Alcohol Dependence
Phase 1CompletedOtsuka Pharmaceutical Co., Ltd.72016-02-012017-04-18
Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge
Nalmefene 18 mg, then placebo, Placebo, then Nalmefene 18 mg - Alcohol Dependence
Phase 1CompletedH. Lundbeck A/S222013-11-012014-11-11
Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects
Nalmefene 18 mg - Renal Impairment
Phase 1CompletedH. Lundbeck A/S322013-07-012016-11-08

Conditions studied

Opiate Overdose (3)  ·  Alcoholism (2)  ·  Opioid-Related Disorders (2)  ·  Alcohol Drinking (1)  ·  HIV Infections (1)  ·  Pain (1)  ·  Renal Insufficiency (1)

Sponsors

Opiant Pharmaceuticals Inc (3)  ·  H. Lundbeck A/S (2)  ·  Boston Medical Center (1)  ·  Knoa Pharma LLC (1)  ·  Leiden University Medical Center (1)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1)  ·  National Institute on Drug Abuse (NIDA) (1)  ·  Otsuka Pharmaceutical Co., Ltd. (1)  ·  Purdue Pharma LP (1)  ·  Tharimmune Inc (1)  ·  Yale University (1)

Countries

United States (9)  ·  Germany (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Russia (1)  ·  United Kingdom (1)

Top investigators

Debra Kelsh, MD (1)  ·  Ingela Danielsson, MD (1)  ·  Jeffrey H. Samet, MD, MA, MPH (1)  ·  Jun-ichi Hashimoto, PhD (1)  ·  Robert Bass, MD (1)  ·  Rutger van der Schrier, MD (1)  ·  Shawn Searle, MD (1)  ·  Vijay A Ramchandani, Ph.D. (1)

Results publications

PMID 37496452, PMID 28216062, PMID 33682527, PMID 37530456, PMID 41642634

NIH funding

UH2AA026193 (1)